Skip to main content
. 2020 Oct 17;9(10):3335. doi: 10.3390/jcm9103335

Figure 3.

Figure 3

phospo-S6 kinase (pS6K) levels in peripheral T cells from Activated Phosphoinositide 3-Kinase Delta Syndrome-1 (APDS-1) patients (Pts). Summarized data for pS6K levels from patients harbouring the Y524D, P658L and R108L PIK3CD mutations are shown for CD4+ T cells (a) and CD8+ T cells (b) after anti-CD3 stimulation and/or CAL-101 treatment. (Data were summarized from n = 3 experiments from the index patients and four different healthy controls (HCs); statistical analysis was performed using the Student’s t-test (* p < 0.05). Abbreviations: a-CD3: anti-CD3, CAL-101: Idelalisib, GS-1101, MFI: mean fluorescence intensity.